The proportion of patients with evidence of breast cancer in preindex was similar in the HER2-targeted (72.7%) and no HER2-targeted cohorts (71.2%), and higher than the no treatment cohort (66.7%) (P < 0.001). The gene discussed is ERBB2; the disease is breast cancer.